肝硬化并发肾上腺皮质功能不全患者的临床特点分析

叶颖剑; 胡乃中

肝硬化并发肾上腺皮质功能不全患者的临床特点分析

安徽医科大学第一附属医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2938
- HTML全文浏览量: 19
- PDF下载量: 677
- 被引次数: 0
出版历程
- 出版日期: 2012-05-20

Clinical analysis of cases of liver cirrhosis complicated with adrenal insufficiency

摘要

摘要: 目的了解肝硬化患者的血清基础皮质醇及促肾上腺皮质激素（ACTH）水平,探讨肝硬化患者并发肾上腺皮质功能不全（AI）的临床意义及特点。方法 118例肝硬化患者用化学发光方法测量血清基础皮质醇及ACTH水平,然后将其分为并发AI组和未并发AI组,前瞻性地分析两组患者的临床特点及预后。同期选取30名胃肠息肉患者为对照组。结果本组肝硬化患者基础皮质醇水平为（329.67±136.1）nmol/L,显著低于对照组的（460.7±165.48）nmol/L（t=-4.501,P<0.05）。肝硬化中并发AI者32例占27.1%（32/118）,AI组与未并发AI的肝硬化患者比较,在并发自发性腹膜炎（SBP）、Child分级、Child评分、MELD评分及病死率方面明显增高,两组差异有统计学意义（P<0.05）;32例并发AI的肝硬化患者白蛋白、高密度脂蛋白-胆固醇（HDL-C）水平明显减低,出现面部色素沉着及腹水的发生率较高（P<0.05）,然而其他临床特点及实验室指标,两组差异无统计学意义。结论肝硬化患者基础皮质醇水平明显减低,并发AI的患者SBP的发生率高、肝损伤的严重、病死...
- 肝硬化 /
- 肾上腺皮质疾病 /
- 肾上腺皮质激素类 /
- 促肾上腺皮质激素
Abstract: Objective To evaluate the baseline level of corticosteroid and adrenocorticotrophic hormone (ACTH) in patients with cirrhosis and to investigate the clinical characteristics in patients with cirrhosis complicated with adrenal insufficiency (AI) .Methods The basal level of corticosteroid and ACTH in 118 liver cirrhosis cases, who were hospitalized in the Department of Gastroenterology in our hospital were measured.Then the patients were divided into two groups as with or without AI.Clinical characteristics and prognosis of the two groups were analyzed.30 cases of gastrointestinal polypus were selected as control.Results The serum corticosteroid in 118 cirrhosis patients was (329.67±136.1) nmol/L, that was lower than that (460.7±165.48) nmol/L in the control group (t=-4.501, P<0.05) .Of 118 cases of cirrhosis, there were 32 cases combining AI and the propotion of them was 27.1% (32/118) .In addition, spontaneous bacterial peritonitis (SBP) complication rates, Child pugh grades and scores, MELD scores and fatality rates of 32 liver cirrhosis cases with AI are all higher than that in the cases without AI (P<0.05) .The level of albumin and high density lipoprotein-cholesterol was lower and the incidence rates of pigmentation, ascites and spontaneous bacterial peritonitis (SBP) are significantly higher (P<0.05) .But there was no statistically significant difference in other clinical characteristics and laboratory parameters (P>0.05) .Conclusion The level of corticosteroid and ACTH in cirrhosis patients is lower, and about 27% cirrhosis cases are complicated with AI, these patients have higher incidence rate of SBP, worse hepatic function and higher mortality, leading to poor prognosis.
- liver cirrhosis /
- adrenal cortex diseases /
- adrenal cortex hormones /
- adrenocorticotrophic hormone

HTML全文

参考文献(14)

[1]Marik PE, Gayowski T, Starzl TE.The hepatoadrenal syn-drome:a common yet unrecognized clinical condition[J].Crit Care Med, 2005, 33 (6) :1254-1259.

[2]Fede G, Spadaro L, Tomaselli T, et al.Assessment of adre-nocortical reserve in stable patients with cirrhosis[J].J Hep-atol, 2011, 54 (2) :243-250.

[3]O'Beirne J, Holmes M, Agarwal B, et al.Adrenal insuffi-ciency in liver disease–what is the evidence[J].J Hepa-tol, 2007, 47 (3) :418-423.

[4]Aravinthan A, Al-Naeeb Y, Richardson P, et al.Relativeadrenal insufficiency in a patient with liver disease[J].Eur JGastroenterol Hepatol, 2009, 21 (4) :471-473.

[5]Galbois A, Rudler M, Massard J, et al.Assessment of adre-nal function in cirrhotic patients:salivary cortisol should bepreferred[J].J Hepatol, 2010, 52 (6) :839-845.

[6]中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南[J], 中华肝脏病杂志, 2005, 13 (z1) :881-891.

[7]McCann VJ, Fulton TT.Cortisol metabolism in chronic liver dis-ease[J].J Clin Endocrinol Metab, 1975, 40 (6) :1038-1044.

[8]Tsai MH, Peng YS, Chen YC, et al.Adrenal insufficiency inpatients with cirrhosis, severe sepsis and septic shock[J].Hepatology, 2006, 43 (4) :673-681.

[9]Wiest R, Moleda L, Zietz B, et al.Uncoupling of sympathet-ic nervous system and hypothalamic-pituitary-adrenal axisin cirrhosis[J].J Gastroenterol Hepatol, 2008, 23 (12) :1901-1908.

[10]Arabi YM, Aljumah A, Dabbagh O, et al.Low-dose hydro-cortisone in patients with cirrhosis and septic shock:a random-ized controlled trial[J].CMAJ, 2010, 182 (18) :1971-1977.

[11]忠弼.病理学[M].北京:人民卫生出版社, 2006:405-419.

[12]Yaguchi H, Tsutsumi K, Shimono K, et al.Involvement ofhigh density lipoprotein as substrate cholesterol for steroido-genesis by bovine adrenal fasciculo-reticularis cells[J].Life Sci, 1998, 62 (16) :1387-1395.

[13]de la Llera-Moya M, Connelly MA, Drazul D, et al.Scav-enger receptor class B type 1 affects cholesterol homeostasisby magnifying cholesterol flux between cells and HDL[J].JLipid Res, 2001, 42 (12) :1969-1978.

[14]Thabut D, Tazi KA, Bonnefont-Rousselot D, et al.High dc-nsity lipoprotein administratjon attcnuates liver prolnflamma-tory response, restores liver endotheIial nitric oxide synthaseactivlty, and lowers portal pressure in cirrhotic rats[J].Hepa-tology, 2007, 46 (6) :1893-1906.

施引文献

资源附件(0)

访问统计